Trial Profile
A German, non-Interventional study of NEPA (fixed dose Netupitant/Palonosetron) for the prevention of chemotherapy induced nausea and vomiting
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 25 Jan 2021
Price :
$35
*
At a glance
- Drugs Netupitant/palonosetron (Primary)
- Indications Chemotherapy-induced nausea and vomiting
- Focus Therapeutic Use
- Acronyms AkyPRO
- 11 Dec 2020 Results of post-hoc analysis assessing quality of life data and effectiveness of NEPA in the subgroup of Breast Cancer patients in two age groups > and <60 years, presented at the 43rd Annual San Antonio Breast Cancer Symposium.
- 08 Dec 2020 Status changed from active, no longer recruiting to completed.
- 08 Dec 2020 Results of quality of life presented at the 62nd Annual Meeting and Exposition of the American Society of Hematology